Accessibility Menu
Artivion logo

Artivion(NYSE) AORT

Market Cap$1.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1993)+563%
5 Year-2%
1 Year-17%
1 Month+11%
$26.13
+3.36%
+0.85Today
Artivion last closing stock price
MetricPriceDate
Last closeUSD 26.102026-07-27
Artivion stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.88%USD 25.372026-07-20
1 month+10.55%USD 23.612026-06-26
3 month-28.16%USD 36.332026-04-28
Year to date-42.78%USD 45.612025-12-31
1 year-16.88%USD 31.402025-07-25
3 year+52.81%USD 17.082023-07-28
5 year-2.06%USD 26.652021-07-28
Since inception+562.63%USD 3.821993-02-12

Artivion Financials at a Glance

Market Cap

$1.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$458.69M

Net Income (TTM)

$11.69M

EPS (TTM)

$0.24

P/E Ratio

105.29

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$26.13

Volume

11,094

Open

$25.67

Previous Close

$26.13

Daily Range

$25.67 - $26.36

52-Week Range

$19.16 - $48.25

Estimated Earnings Date

Aug 6, 2026

AORT News

BuyAlert-Red.png

Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top Holding

Seena HassounaMay 17, 2026
Foolcom-Featured.png

Artivion (AORT) Q2 EPS Jumps 243%

Motley Fool Markets TeamAug 7, 2025
Medical professional holding dollar sign paperweight

Why Artivion Stock Popped on Friday

Eric VolkmanFeb 17, 2023
Heart

Why CryoLife Inc. Jumped Higher

Brian Orelli, PhDApr 27, 2017
On-X-Aortic-Heart-Valve-with-Conform-X-sewing-ring

Why Cryolife Inc's Shares Turned Hot Today

Brian Orelli, PhDJul 26, 2016

Why CryoLife, Inc. Shares Have Gone Ice-Cold

Sean WilliamsFeb 20, 2014

Why CryoLife Inc. Shares Zipped Higher

Sean WilliamsOct 29, 2013

1 Reason CryoLife's Earnings Aren't So Hot

Seth JaysonJul 23, 2013
Page 1

AORT: Motley Fool Moneyball Superscore

69

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Artivion

Artivion helps doctors treat life-threatening heart and artery diseases. They make replacement heart valves and artery repair tools. Their products help patients with heart damage live longer lives.

Tools for Complex Surgeries

  • Aortic Stent Grafts: Fabric-covered metal tubes that reinforce or repair the aorta, which is the body's main artery.
  • On-X Heart Valves: Specialized mechanical valves used to replace failing native heart valves in the aortic or mitral positions.
  • Surgical Sealants: Medical adhesives like BioGlue that help surgeons stop bleeding and seal internal wounds during operations.
  • Preservation Services: Processing and storage of donated human heart and vascular tissues for use in medical transplants.

Key Acquisitions and Deals

  • Acquired JOTEC in December 2017 to expand its portfolio of grafts for the treatment of aortic disease.
  • Bought On-X Life Technologies in January 2016 to gain access to advanced mechanical heart valve technology.
  • Acquired Ascyrus Medical in September 2020 for its specialized device that repairs the aortic arch.
  • Partnered with Endospan in September 2019 to distribute a unique family of stent grafts in certain international markets.
  • Sold the PerClot product line to Baxter in July 2021 while continuing to serve as the manufacturer.

Specialized Global Infrastructure

Artivion operates manufacturing facilities in the United States and Germany to support its global distribution network. The company holds a unique regulatory status for its mechanical heart valves, which allow for lower doses of blood-thinning medication.

Growth by the Numbers

  • Revenue reached $116 million in Q4 2025, up 19.2% from the same period in 2024.
  • Operating income reached $7.2 million in Q4 2025, a 169% increase over the previous year.
  • Net income turned positive at $2.4 million in Q4 2025, improving from a $16.5 million loss.
  • Operating cash flow hit $19.6 million in Q4 2025, up 92.9% year-over-year.
  • Free cash flow fell to negative $7.9 million in Q4 2025, worsening from $8.7 million.

The Evolution of Artivion

Artivion has transitioned from a tissue processing firm into a specialized global medical device manufacturer. Its focused portfolio addresses complex needs in aortic repair and cardiac surgery through both mechanical products and preserved human tissues.

AI Generated • Apr 29, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

1,800

CEO

James Patrick Mackin, MBA

Website

www.artivion.com

Headquarters

Kennesaw, GA 30144, US

AORT Financials

Key Financial Metrics (TTM)

Gross Margin

62.94%

Operating Margin

7.76%

Net Income Margin

2.55%

Return on Equity

2.66%

Return on Capital

3.61%

Return on Assets

1.32%

Earnings Yield

0.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

48.54M

Volume

11.09K

Avg. Volume

787.17K

Financials (TTM)

Gross Profit

$288.70M

Operating Income

$35.59M

EBITDA

$65.05M

Operating Cash Flow

$56.24M

Capital Expenditure

-$43.41M

Free Cash Flow

$12.83M

Cash & ST Invst.

$55.76M

Total Debt

$258.16M

Artivion Performance Analysis

Artivion annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 313,789,0005.0%
20232023-12-31USD 354,004,00012.8%
20242024-12-31USD 388,537,0009.8%
20252025-12-31USD 441,330,00013.6%
Artivion sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3014.1%
Q32025-09-300.4%
Q42025-12-312.3%
Q12026-03-310.3%
Artivion annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.4826.2%
20232023-12-31USD -0.7557.3%
20242024-12-31USD -0.32-57.3%
20252025-12-31USD 0.21N/A
Artivion sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30348.7%
Q32025-09-30339.2%
Q42025-12-31-62.4%
Q12026-03-31-41.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$116.34M

+17.5%

Gross Profit

$71.54M

+12.5%

Gross Margin

61.49%

N/A

Market Cap

$1.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$681.76K

N/A

Employees

1,800

N/A

Net Income

$1.42M

+380.6%

EBITDA

$12.05M

+11.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$55.76M

+47.9%

Total Debt

$258.16M

-28.8%

Accounts Receivable

$105.62M

+10.3%

Inventory

$98.00M

+19.6%

Long Term Debt

$252.63M

-29.2%

Short Term Debt

$5.53M

+2.8%

Return on Assets

1.32%

N/A

Return on Invested Capital

4.50%

N/A

Free Cash Flow

-$6.85M

+66.7%

Operating Cash Flow

$1.15M

+106.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PRCTPROCEPT BioRobotics Corporation
$17.69+5.99%
INSPInspire Medical Systems, Inc.
$50.93+3.54%
ARDTArdent Health Inc.
$10.95+2.91%
SSIISS Innovations International, Inc.
$3.96+13.96%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About AORT

What is the current price of Artivion?

Artivion is trading at $26.13 per share.

What is the 52-week range for Artivion?

Over the past 52 weeks, Artivion has traded between $19.16 and $48.25.

How much debt does Artivion have?

As of the most recent reporting period, Artivion reported total debt of $258.16M.

How much cash does Artivion have on hand?

Artivion reported $55.76M in cash and cash equivalents in its most recent financial results.

What is Artivion’s dividend yield?

Artivion does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services